Hyperfine to Announce Fourth Quarter and Full Year 2021 Financial Results

Rhea-AI Summary

Hyperfine, Inc. (Nasdaq: HYPR) will announce its financial results for Q4 and full-year 2021 on March 23, 2022, followed by a conference call at 1:30 p.m. PT / 4:30 p.m. ET. The company developed Swoop®, the first FDA-cleared portable MRI system, aimed at enhancing patient access to diagnostic imaging. Swoop's affordability and ease of use allow rapid diagnoses in various clinical settings, offering high-quality imaging at lower magnetic field strengths.

Positive

• Swoop® is the first FDA-cleared portable MRI system, expanding access to diagnostic imaging.
• Designed for rapid diagnoses, Swoop allows quick scans and treatment at the patient's bedside.
• Swoop's lower cost compared to conventional MRIs enhances financial accessibility.

Negative

• None.

GUILFORD, CT, March 03, 2022 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the creator of Swoop®, the world's first FDA-cleared portable MRI system™, today announced that it will report financial results for the fourth quarter and full year 2021 on Wednesday, March 23, 2022. Company management will host a corresponding conference call to discuss the financial results and provide a business update beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (888) 708-1168 for domestic callers or (630) 652-5889 for international callers, using conference ID 8268432. A live audio webcast and an archive of the presentation will be available through the Investors page of Hyperfine’s corporate website at https://investors.hyperfine.io/.

About Hyperfine
Hyperfine, Inc. is the groundbreaking medical device company that created Swoop®, the world’s first FDA-cleared portable MRI system™. Hyperfine designed Swoop to enable rapid diagnoses and treatment for every patient regardless of income, resources, or location, pushing the boundaries of conventional imaging technology and expanding patient access to life-saving care. The Swoop Portable MR Imaging System™ produces high-quality images at a lower magnetic field strength, allowing clinicians to quickly scan, diagnose, and treat patients in various clinical settings. Swoop can be wheeled directly to the patient’s bedside, plugged into a standard electrical wall outlet, and controlled by an iPad®. Designed as a complementary system to conventional MRIs at a fraction of the cost, Swoop captures images in minutes, providing critical decision-making capabilities in emergency departments, operating rooms outside the sterile field, and intensive care units, among others.

Investor Contact
Marissa Bych
Gilmartin Group LLC
investors@hyperfine.io

Media Contact        
Aunny De La Rosa-Bathe
APCO Worldwide
abathe@apcoworldwide.com 

FAQ

When will Hyperfine report its Q4 2021 results?

Hyperfine will report its Q4 and full-year 2021 results on March 23, 2022.

What is Hyperfine's stock symbol?

Hyperfine's stock symbol is HYPR.

How can I listen to Hyperfine's conference call?

Investors can listen to the conference call by dialing (888) 708-1168 for domestic callers or (630) 652-5889 for international callers.

What is the Swoop® system?

Swoop® is the world's first FDA-cleared portable MRI system designed to enable rapid diagnoses and treatment.

What are the benefits of the Swoop® MRI system?

Swoop® provides high-quality imaging at a lower magnetic field strength, allowing clinicians to quickly diagnose and treat patients in various settings.